Aljehani, A.
Kew, T.
Baig, S.
Cox, H.
Sommerfeld, L. C.
Ensam, B.
Kalla, M.
Steeds, R. P.
Fabritz, L.
Funding for this research was provided by:
EU Horizon 2020 MAESTRIA (965286)
Article History
Received: 28 June 2022
Accepted: 19 December 2022
First Online: 12 January 2023
Declarations
:
: All experimental protocols were approved by the local clinical governance committee (audit number: Clinical Audit Registration and Management system by Birmingham’s Children’s Hospital Clinical Audit and Effectiveness Lead/University Hospital’s Birmingham, ((CARMS)-16044, 17734) and conformed to the Good Clinical Practice guidelines. The local clinical governance committee has the authority to approve and waive the ethical approval and informed consent. All methods were performed in accordance with the relevant guidelines and regulations. As this observational study was performed as part of an audit ((CARMS)-16044, 17734) in patients receiving standard NHS care, the clinical audit committee by Birmingham’s Children’s Hospital Clinical Audit and Effectiveness Lead/University Hospital’s Birmingham thereby waived the need of informed consent. From 2020, patients have given Human Biomaterial Resource Centre (HBRC), a Human Tissue Authority (HTA) licensed human sample biorepository operated by the University of Birmingham informed consent to provide blood samples and clinical data (study title: Heartbeat Matrix Pilot: Accelerating targeted treatments for patients with inherited heart diseases. REC reference: 20/LO/0184 IRAS project ID: 269251, REC name: London—West London & GTAC Research Ethics Committee).
: Not applicable.
: The authors declare no competing interests to the work in this submission.